Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800492 | 1.00 | TACR1 (0.53) | TACR1 | |
| SCHEMBL4024519 | 0.90 | TACR1 (0.61) | TACR1 | |
| SCHEMBL3320562 | 0.90 | TACR1 (0.61) | TACR1 | |
| SCHEMBL3315691 | 0.90 | TACR1 (0.61) | TACR1 | |
| SCHEMBL2487726 | 0.86 | TACR1 (0.54) | TACR1 | |
| SCHEMBL2487727 | 0.86 | TACR1 (0.54) | TACR1 | |
| SCHEMBL6064294 | 0.83 | TACR1 (0.54) | TACR1 | |
| SCHEMBL6064290 | 0.83 | TACR1 (0.54) | TACR1 | |
| SCHEMBL3321346 | 0.83 | TACR1 (0.43) | TACR1 | |
| SCHEMBL3321343 | 0.83 | TACR1 (0.43) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135414-A1 | Tachykinin Antagonists | ALVARO GUISEPPE | 2007-06-14 | — | — | US | claimed |
| EP-1377558-B1 | [1,4]-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LTD (GB) | 2005-08-17 | — | — | EP | claimed |
| US-20040127485-A1 | 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2004-07-01 | — | — | US | claimed |
| EP-1377558-A1 | [1,4]-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | claimed |
| WO-2002081457-A1 | `1,4!-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-10-17 | — | — | WO | claimed |
| US-20180021327-A1 | TREATMENT OF CORNEAL NEOVASCULARIZATION | IRBM SCIENCE PARK S.P.A. (IT) | 2018-01-25 | — | — | US | disclosed |
| US-9782397-B2 | Treatment of corneal neovascularization | IRBM SCIENCE PARK S.P.A. (IT) | 2017-10-10 | — | — | US | disclosed |
| EP-2729147-B1 | NK-1 RECEPTOR ANTAGONISTS FOR TREATING CORNEAL NEOVASCULARISATION | IRBM - SCIENCE PARK S P A (IT) | 2017-09-06 | — | — | EP | disclosed |
| US-20140128395-A1 | Novel Method | IRBM SCIENCE PARK S.P.A. (IT) | 2014-05-08 | — | — | US | disclosed |
| US-20070135414-A1 | Tachykinin Antagonists | ALVARO GUISEPPE | 2007-06-14 | — | — | US | disclosed |
| US-7196077-B2 | Tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| EP-1377558-B1 | [1,4]-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LTD (GB) | 2005-08-17 | — | — | EP | disclosed |
| US-20040127485-A1 | 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1377558-A1 | [1,4]-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002081457-A1 | `1,4!-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127485-A1 | 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists | NPY1R, CRHR1, GRIN1 | TACR1 24/4885 |
| US-20070135414-A1 | Tachykinin Antagonists | NPSR1, TACR2, NPY4R | TACR1 7/4885 |
| US-20140128395-A1 | Novel Method | BAK1, VIPR1, BDKRB1 | TACR1 38/4885 |
| US-20180021327-A1 | TREATMENT OF CORNEAL NEOVASCULARIZATION | KDR, BAK1, FLT1 | TACR1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.